van der Aart-van der Beek, Annemarie B. http://orcid.org/0000-0003-1473-3259
de Boer, Rudolf A. http://orcid.org/0000-0002-4775-9140
Heerspink, Hiddo J. L. http://orcid.org/0000-0002-3126-3730
Article History
Accepted: 7 January 2022
First Online: 10 February 2022
Competing interests
: R.A.d.B has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis and Roche, is on the Executive Committee of the Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) trial, sponsored by AstraZeneca, and is a study group member of the Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction (DETERMINE Reduced & Preserved) trials, sponsored by AstraZeneca. H.J.L.H. has consulting relationships with AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Pharma, Chinook, Dimerix, Gilead, Janssen, Merck, Mitsubishi Tanabe, Mundi Pharma, NovoNordisk and Travere. A.B.v.d.A.-v.d.B. declares no competing interests.